信达证券发布九洲药业研报，CDMO业务保持高增长，新分子业务布局有望打造全新增长点

Group 1 - The core viewpoint of the report is that JiuZhou Pharmaceutical (603456.SH, latest price: 18.05 yuan) is rated positively due to its stable operational trends and high growth in CDMO (Contract Development and Manufacturing Organization) business [2] - The company is accelerating the layout of new molecular businesses to create new growth points [2] Group 2 - The report highlights the robust growth of the CDMO business as a key factor for the positive rating [2] - The company is focusing on expanding its new molecular business, which is expected to contribute to future growth [2]